<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Fresenius-Medical-Care-AG-Co-KGaA-Sponsored-ADR-US3580291066">Fresenius Medical Care AG &amp; Co. KGaA Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Proactive Investors</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.proactiveinvestors.co.uk/companies/news/1095944?SNAPI">Hikma und Fresenius am besten positioniert durch Trumps Strafzölle auf Generika, sagt Citi</a>
    </div>

      <div class="me-0 me-md-5">
        Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) und Fresenius Medical Care (NYSE:FMS) könnten sich laut Citi als relative Gewinner aus den von Donald Trump vorgeschlagenen Zöllen auf Generika herausbilden, weil sie umfangreiche US-Fertigungsaktivitäten besitzen. Der US-Präsident kündigte diese Woche Pläne an, ab August 2028 auf importierte Generika einen Zoll von 100 % zu erheben, der ein Jahr s...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Fresenius-Medical-Care-AG-Co-KGaA-Sponsored-ADR-US3580291066">Fresenius Medical Care AG &amp; Co. KGaA Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/fresenius-medical-care-launches-kinexus-worldwide-a-unified-digital-platform-to-support-home-dialysis-302789705.html">Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis</a>
    </div>

      <div class="me-0 me-md-5">
        Global launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programs Designed to simplify care processes for healthcare teams and their patients to support high-quality, personalized care for patients dialyzing at home Enables managing peritoneal dialysis and home hemodialysis therapies across Fresenius Medical Care&#39;s g...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Fresenius-Medical-Care-AG-Co-KGaA-Sponsored-ADR-US3580291066">Fresenius Medical Care AG &amp; Co. KGaA Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/fresenius-medical-care-launches-first-tranche-of-its-share-buyback-program-of-up-to-eur-600-million-302784358.html">Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million</a>
    </div>

      <div class="me-0 me-md-5">
        BAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world&#39;s leading provider of products and services for individuals with renal diseases, today announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1 billion. The first tranche, amounting up to EUR 600 million, was initiated today and is expected to be compl...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Fresenius-Medical-Care-AG-Co-KGaA-Sponsored-ADR-US3580291066">Fresenius Medical Care AG &amp; Co. KGaA Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/fresenius-medical-care-highlights-new-renal-research-and-innovation-at-era-congress-2026-302783113.html">Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026</a>
    </div>

      <div class="me-0 me-md-5">
        Hemodiafiltration (HDF) research reinforces Fresenius Medical Care&#39;s continued leadership in advancing evidence-based dialysis care and treatment personalization New research focuses on applying real-world evidence, patient-centered outcomes and artificial intelligence across dialysis modalities and continuity of kidney care A preview of kinexus, a unified digital platform intended to support h...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Fresenius-Medical-Care-AG-Co-KGaA-Sponsored-ADR-US3580291066">Fresenius Medical Care AG &amp; Co. KGaA Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/fresenius-medical-care-announces-new-share-buyback-program-with-a-total-volume-of-around-eur-1-billion-with-phased-execution-over-12-months-302781709.html">Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months</a>
    </div>

      <div class="me-0 me-md-5">
        Total volume of the share buyback is around EUR 1 billion over 12 months Share buyback expected to begin in the near future BAD HOMBURG, Germany, May 26, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world&#39;s leading provider of products and services for individuals with renal diseases, intends to execute a new share buyback program with a total volume of around EUR 1 billion. The progr...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Fresenius-Medical-Care-AG-Co-KGaA-Sponsored-ADR-US3580291066">Fresenius Medical Care AG &amp; Co. KGaA Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/fresenius-medical-care-annual-general-meeting-strengthening-performance-and-advancing-innovation-in-kidney-care-302779080.html">Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care</a>
    </div>

      <div class="me-0 me-md-5">
        Shareholders approve proposed dividend of EUR 1.49 per share FME Reignite strategy launched in 2025 successfully drives the next phase of value creation 5008X CAREsystem introduced in U.S. clinics; full U.S. commercial launch underway in 2026 EUR 1 billion share buyback program successfully completed, and a new authorization granted to support the Company&#39;s capital allocation framework which in...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Fresenius-Medical-Care-AG-Co-KGaA-Sponsored-ADR-US3580291066">Fresenius Medical Care AG &amp; Co. KGaA Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/fresenius-medical-care-reappoints-chief-financial-officer-martin-fischer-302778002.html">Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer</a>
    </div>

      <div class="me-0 me-md-5">
        BAD HOMBURG, Germany, May 20, 2026 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care AG, the world&#39;s leading provider of products and services for individuals with renal disease, today has reappointed Chief Financial Officer (CFO) and Management Board Member Martin Fischer (49) for a period of five years until 2031. Michael Sen, Chairman of the Supervisory Board, commented, &quot;Marti...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Fresenius-Medical-Care-AG-Co-KGaA-Sponsored-ADR-US3580291066">Fresenius Medical Care AG &amp; Co. KGaA Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/fresenius-medical-care-delivers-strong-operating-income-growth-in-q1-2026-while-advancing-the-us-rollout-of-5008x-caresystems-at-speed-302762540.html">Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed</a>
    </div>

      <div class="me-0 me-md-5">
        Organic revenue growth1 of 4% with growth in all operating segments Operating income2 grew 10%, resulting in further margin expansion to 10.1% FME25+ transformation program related one-time costs mainly drove reported operating income decline of 14% and reported net income3 decrease of 22% Earnings per share2 (EPS) increased by 16%, supported by the share buyback program FY 2026 outlook confirm...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Fresenius-Medical-Care-AG-Co-KGaA-Sponsored-ADR-US3580291066/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>